Literature DB >> 25174872

IL-10/Janus kinase/signal transducer and activator of transcription 3 signaling dysregulates Bim expression in autoimmune lymphoproliferative syndrome.

Omar Niss1, Allyson Sholl2, Jack J Bleesing1, David A Hildeman3.   

Abstract

BACKGROUND: Autoimmune lymphoproliferative syndrome (ALPS) is a human disorder of T cell homeostasis caused by mutations that impair FAS-mediated apoptosis. A defining characteristic of ALPS is the expansion of double negative T cells (DNTC). Relatively little is known about how defective FAS-driven cell death and the Bcl-2 apoptotic pathway intersect in ALPS patients.
OBJECTIVE: We studied changes in Bcl-2 family member expression in ALPS to determine whether the Bcl-2 pathway might provide a therapeutic target.
METHODS: We used flow cytometry to analyze the expression of pro- and anti-apoptotic Bcl-2 family members in T cells from 12 ALPS patients and determined the in vitro sensitivity of ALPS DNTC to the pro-apoptotic BH3 mimetic, ABT-737.
RESULTS: The pro-apoptotic molecule, Bim, was significantly elevated in DNTC. Although no general pattern of individual anti-apoptotic Bcl-2 family members emerged, increased expression of Bim was always accompanied by increased expression of at least 1 anti-apoptotic Bcl-2 family member. Strikingly, Bim levels in DNTC correlated significantly with serum IL-10 in ALPS patients, and IL-10 was sufficient to mildly induce Bim in normal and ALPS T cells via a Janus kinase/signal transducer and activator of transcription 3-dependent mechanism. Finally, ABT-737 preferentially killed ALPS DNTC in vitro.
CONCLUSION: Combined, these data show that an IL-10/Janus kinase/signal transducer and activator of transcription 3 pathway drives Bim expression in ALPS DNTC, which renders them sensitive to BH3 mimetics, uncovering a potentially novel therapeutic approach to ALPS.
Copyright © 2014 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ABT-737; ALPS; BH3 mimetic; Bcl-2 pathway; Bim; IL-10; T cell homeostasis; apoptosis; double negative T cells

Mesh:

Substances:

Year:  2014        PMID: 25174872      PMCID: PMC4344440          DOI: 10.1016/j.jaci.2014.07.020

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  73 in total

1.  IL-10 induces regulatory T cell apoptosis by up-regulation of the membrane form of TNF-alpha.

Authors:  Luciano E Marra; Zhu X Zhang; Betty Joe; Jon Campbell; Gary A Levy; Josef Penninger; Li Zhang
Journal:  J Immunol       Date:  2004-01-15       Impact factor: 5.422

2.  BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs.

Authors:  Emma M Carrington; Ingela B Vikstrom; Amanda Light; Robyn M Sutherland; Sarah L Londrigan; Kylie D Mason; David C S Huang; Andrew M Lew; David M Tarlinton
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-01       Impact factor: 11.205

3.  Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.

Authors:  Mai Nguyen; Richard C Marcellus; Anne Roulston; Mark Watson; Lucile Serfass; S R Murthy Madiraju; Daniel Goulet; Jean Viallet; Laurent Bélec; Xavier Billot; Stephane Acoca; Enrico Purisima; Adrian Wiegmans; Leonie Cluse; Ricky W Johnstone; Pierre Beauparlant; Gordon C Shore
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-26       Impact factor: 11.205

4.  The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2.

Authors:  Marie Stahl; Pascale F Dijkers; Geert J P L Kops; Susanne M A Lens; Paul J Coffer; Boudewijn M T Burgering; René H Medema
Journal:  J Immunol       Date:  2002-05-15       Impact factor: 5.422

5.  The NF-kappa B cascade is important in Bcl-xL expression and for the anti-apoptotic effects of the CD28 receptor in primary human CD4+ lymphocytes.

Authors:  A Khoshnan; C Tindell; I Laux; D Bae; B Bennett; A E Nel
Journal:  J Immunol       Date:  2000-08-15       Impact factor: 5.422

6.  U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis.

Authors:  Albert Deisseroth; Edvardas Kaminskas; Joseph Grillo; Wei Chen; Haleh Saber; Hong L Lu; Mark D Rothmann; Satjit Brar; Jian Wang; Christine Garnett; Julie Bullock; Laurie B Burke; Atiqur Rahman; Rajeshwari Sridhara; Ann Farrell; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2012-04-27       Impact factor: 12.531

7.  Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation.

Authors:  Masatoshi Takagi; Kunihiro Shinoda; Jinhua Piao; Noriko Mitsuiki; Mari Takagi; Kazuyuki Matsuda; Hideki Muramatsu; Sayoko Doisaki; Masayuki Nagasawa; Tomohiro Morio; Yoshihito Kasahara; Kenichi Koike; Seiji Kojima; Akira Takao; Shuki Mizutani
Journal:  Blood       Date:  2010-11-09       Impact factor: 22.113

8.  Human TCR alpha/beta+ CD4-CD8- double-negative T cells in patients with autoimmune lymphoproliferative syndrome express restricted Vbeta TCR diversity and are clonally related to CD8+ T cells.

Authors:  Anne Bristeau-Leprince; Véronique Mateo; Annick Lim; Aude Magerus-Chatinet; Eric Solary; Alain Fischer; Frédéric Rieux-Laucat; Marie-Lise Gougeon
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

9.  Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1.

Authors:  Joseph T Opferman; Anthony Letai; Caroline Beard; Mia D Sorcinelli; Christy C Ong; Stanley J Korsmeyer
Journal:  Nature       Date:  2003-12-11       Impact factor: 49.962

10.  Reduced development of CD4-8-B220+ T cells but normal autoantibody production in lpr/lpr mice lacking major histocompatibility complex class I molecules.

Authors:  T Ohteki; M Iwamoto; S Izui; H R MacDonald
Journal:  Eur J Immunol       Date:  1995-01       Impact factor: 5.532

View more
  5 in total

1.  CD151 Expression Is Associated with a Hyperproliferative T Cell Phenotype.

Authors:  Lillian Seu; Christopher Tidwell; Laura Timares; Alexandra Duverger; Frederic H Wagner; Paul A Goepfert; Andrew O Westfall; Steffanie Sabbaj; Olaf Kutsch
Journal:  J Immunol       Date:  2017-09-27       Impact factor: 5.422

Review 2.  Dying to protect: cell death and the control of T-cell homeostasis.

Authors:  Kun-Po Li; Sharmila Shanmuganad; Kaitlin Carroll; Jonathan D Katz; Michael B Jordan; David A Hildeman
Journal:  Immunol Rev       Date:  2017-05       Impact factor: 12.988

Review 3.  Advances in clinical immunology in 2015.

Authors:  Javier Chinen; Luigi D Notarangelo; William T Shearer
Journal:  J Allergy Clin Immunol       Date:  2016-12       Impact factor: 10.793

4.  P-STAT3 Inhibition Activates Endoplasmic Reticulum Stress-Induced Splenocyte Apoptosis in Chronic Stress.

Authors:  Manyu Song; Chaoran Wang; Haotian Yang; Yongping Chen; Xiujing Feng; Bei Li; Honggang Fan
Journal:  Front Physiol       Date:  2020-06-30       Impact factor: 4.566

Review 5.  Gain-of-function defects in toll-like receptor 8 shed light on the interface between immune system and bone marrow failure disorders.

Authors:  Jack Bleesing
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.